NORTHVALE, N.J.--(BUSINESS WIRE)--Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (AMEX: ELI), has been selected to present at The Roth Capital 19th OC Conference in Dana Point, California, on Tuesday, February 20th, 2007 at 4:00 PM PST (7:00 PM EST). Bernard Berk, Elite’s Chairman and Chief Executive Officer will provide an update on the developments of the Company’s two lead opioid products: ELI-216, the Company’s abuse-deterrent oxycodone hydrochloride product using ART™, and ELI-154, its once-daily oxycodone hydrochloride product along with its pipeline of other oral controlled-release products addressing niche markets.
